Re-Thinking Clinical Trials in Oncology
 Assessing the landscape of novel trial design for cancer therapies to improve data collection, enhance patient access, and drive clinical outcomes for breakthrough therapies

October 28, 2020 | Live Virtual Forum (EST)

Dr. Kevin Knopf MD

Division Chief Hematology/Oncology Highland Hospital/ Alameda Health System

Kevin Knopf MD, MPH is Division Chief of Hematology/Oncology at Highland Hospital, Oakland, California. He is also a health economist and health services researcher whose research focuses on cost-effectiveness, patterns and quality of care in oncology, and health disparities in cancer screening, diagnosis and treatment. He trained at the National Cancer Institute Medicine Branch and the Health Services and Economics Research Branch after receiving an undergraduate degree at the Massachusetts Institute of Technology and his medical degree at the University of California, San Francisco School of Medicine. He completed his clinical training at Northwestern Medical School, Sloan Kettering Cancer Center and received an MPH in Epidemiology and Statistics at Johns Hopkins School of Public Health. He is currently Assistant Clinical Professor at the University of California, San Francisco and and a member of the Institute for Health Policy as well as an Associate Professor of Pharmaco-economics at the University of South Carolina School of Pharmacy. Twitter: @drkevinknopf

WEDNESDAY, OCTOBER 28

12:30 PM Improving Diversity, Inclusion & Health Equity in Cancer Clinical Trials

Disparate rates of enrollment of racial and ethnic minorities and medically underserved populations in cancer clinical trials is well documented. Understand how this factor not only impacts the validity of trial results and increases health disparities for under-served communities and patients. Explore how trials might engage novel strategies to diversify their studies and also the wider social and economic factors affecting health equity that need to be addressed to truly overcome barriers for cancer patients from underrepresented populations.